Advertisement

Topics

NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer

04:56 EDT 21 Jun 2017 | Elsevier Business Intelligence

After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA body NICE...

Original Article: NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...